Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective

GLP1 receptor agonists (GLP1-RAs) are drugs that mimic the effects of the incretin hormone GLP1 and were initially introduced in medicine for the treatment of diabetes in 2005 and for obesity in 2014. Over time, data from secondary and exploratory objectives of large randomized controlled-trials sug...

Full description

Autores:
Rico-Fontalvo, Jorge
Reina, Maricely
Soler, María José
Unigarro-Palacios, Mario
Castañeda González, Juan Pablo
Jiménez Quintero, Javier
Raad Sarabia, Maria Isabel
Proenca de Moraes, Thyago
Daza-Arnedo, Rodrigo
Tipo de recurso:
Fecha de publicación:
2024
Institución:
Universidad Simón Bolívar
Repositorio:
Repositorio Digital USB
Idioma:
spa
OAI Identifier:
oai:bonga.unisimon.edu.co:20.500.12442/15936
Acceso en línea:
https://hdl.handle.net/20.500.12442/15936
https://doi.org/10.1590/2175-8239-JBN-2024-0101en
https://www.bjnephrology.org/en/article/kidney-effects-of-glucagon-like-peptide-1-glp1-from-molecular-foundations-to-a-pharmacophysiological-perspective/
Palabra clave:
Albuminuria
Diabetes
Incretins
Obesity
Kidney disease
Albuminúria
Diabetes
Incretinas
Obesidade
Doença Renal
Rights
openAccess
License
Attribution-NonCommercial-NoDerivs 3.0 United States